Client Overview
The client, a European-based multinational pharmaceutical company, manufactures both branded and generic formulations for therapeutic categories such as cardiovascular health, central nervous system disorders, and anti-infectives.
- The company sources APIs such as Atorvastatin, Metformin, and Amoxicillin primarily from India and China.
- Procurement challenges included price opacity, dependence on a few large API suppliers, and regulatory-driven trade fluctuations.
Research Objective
The engagement aimed to provide procurement teams with a transparent, data-backed pricing framework to:
- Benchmark API prices across major producer countries.
- Analyze import/export flows by HS code to identify top supplier markets.
- Build should-cost ladders for selected APIs to dissect supplier quotes into feedstock, utilities, labor, freight, and duty components.
- Forecast future API pricing trends (2026–2030) to support long-term procurement contracts.
Scope of Work
FMI’s role was to design a comprehensive procurement intelligence solution including:
- API Pricing Index (API-PI): Monthly normalized series for 20+ APIs, differentiated by country, grade, and Incoterm (FOB/CIF/Ex-Works).
- Market Pricing Dataset: Historical (2018-2025) + Forecast (2026-2030F) with MoM/YoY deltas, volatility, and rolling averages.
- Trade Flow Dashboard: Import/export volumes and unit values (HS 293500, 300490, etc.), top exporters (India, China, EU), and tariff notes.
- Should-Cost Analysis: Breakdowns of raw material costs, intermediates, solvents, utilities, labor, freight, duties, and producer margins.
- Supplier Quote Triangulation: Triangulated ranges built from distributor lists, tender portals, and qualified quotes, anonymized for procurement benchmarking.
FMI’s Approach & Solution
Step 1 - Global API Pricing Index
- Constructed monthly normalized price series for APIs such as Atorvastatin (cardiovascular), Metformin (diabetes), and Amoxicillin (antibiotics).
- Incorporated Incoterm differentials: FOB India, CIF US/EU, Ex-Works China.
Step 2 - Trade Flow Mapping
- Analyzed 7 years of customs trade data across India, China, and EU.
- Highlighted India’s dominance in antibiotic APIs, while China controlled a large share of statin intermediates.
- Identified seasonal shipment peaks and port congestion periods that affected CIF costs.
Step 3 - Should-Cost Modeling
- Built cost ladders for APIs showing contribution breakdowns:
- Raw material/intermediates: ~60-70%
- Utilities: ~10-15%
- Labor & overhead: ~8-10%
- Freight & duties: ~5-8%
- Conducted sensitivity analysis to simulate shocks (e.g., +15% solvent costs, +20% energy).
Step 4 - Supplier Triangulation
- Consolidated anonymized supplier quotes from India, China, and European distributors.
- Developed monthly min/median/max price bands to serve as procurement’s negotiation baseline.
Outcome & Impact
- Cost Savings: Negotiated 8-12% lower API prices compared to initial supplier quotes by referencing should-cost and triangulated ranges.
- Supply Diversification: Reduced dependency on China for statin intermediates by contracting with secondary suppliers in India and Eastern Europe.
- Risk Mitigation: Identified tariff exposure in US imports post-regulation changes and realigned procurement volumes accordingly.
- Faster Procurement Cycles: Reduced RFQ turnaround time by 25-30%, as procurement had data-backed benchmarks.
- Forecast Planning: Integrated 5-year forecasts into procurement strategy, improving budget
Key Recommendations
- Adopt Multi-Origin Sourcing: Reduce reliance on a single-country API supply chain by maintaining at least 2-3 qualified suppliers.
- Strengthen Contract Structures: Use FMI’s forecast models to implement escalation/de-escalation clauses linked to feedstock and energy indices.
- Monitor Energy & Solvent Costs: Track volatility in Chinese energy markets and global solvent prices as they directly impact API production costs.
- Quarterly Updates: Refresh the API Pricing Index quarterly to ensure supplier negotiations remain aligned with market reality.
- Strategic Supplier Partnerships: Build closer ties with Indian API manufacturers for antibiotics and cardiovascular drugs to diversify away from single-origin dependency.
